Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain

mAbs

Volumn 4, Issue 4, 2012, Pages 497-508

  Schlatter, Daniel ^a   Brack, Simon ^b   Banner, David W ^a,c   Batey, Sarah ^b,d   Benz, Jörg ^a   Bertschinger, Julian ^b   Huber, Walter ^a   Joseph, Catherine ^a   Rufer, Arne C ^a   Van Der Klooster, Anita ^a   Weber, Martin ^a   Grabulovski, Dragan ^b   Hennig, Michael ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Covagen AG ^*  (Switzerland)

^c Portway Building ^*  (Switzerland)

^d Babraham Research Campus   (United Kingdom)

Author keywords

Biacore; Crystal structure; Enzyme inhibitor; Fynomers; Serine protease

Indexed keywords

BINDING PROTEIN; CHYMASE; FYNOMER; PROTEIN KINASE FYN; PROTEIN SH3; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; IC 50; MAST CELL; PHAGE DISPLAY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS;

EID: 84863448581     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.20452     Document Type: Article

References (36)

1. Shea-Donohue T, Stiltz J, Zhao A, Notari L. Mast cells. Curr Gastroenterol Rep 2010; 12:349-57; PMID:20711694; http://dx.doi.org/10.1007/ s11894-010-0132-1.
2. Miller HRP, Pemberton AD. Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology 2002; 105:375-90; PMID:11985658; http://dx.doi.org/10.1046/j.1365- 2567.2002.01375.x.
3. de Garavilla L, Greco MN, Sukumar N, Chen ZW, Pineda AO, Mathews FS, et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem 2005; 280:18001-7; PMID:15741158; http://dx.doi.org/10.1074/jbc.M501302200.
4. Takai S, Jin D, Miyazaki M. New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 2010; 113:301-9; PMID:20675958; http://dx.doi.org/10.1254/jphs.10R05FM.
5. Maryanoff BE, de Garavilla L, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med 2010; 181:247-53; PMID:19875688; http://dx.doi.org/10.1164/rccm.200904-0627OC.
6. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, et al. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2- ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003; 305:17-23; PMID:12649348; http://dx.doi.org/10.1124/jpet.102.045179.
7. Doggrell SA, Wanstall JC. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol 2005; 83:123-30; PMID:15791285; http://dx.doi.org/10.1139/y04-136.
8. Diaconu NC, Rummukainen J, Naukkarinen A, MättöM, Harvima RJ, Pelkonen J, et al. Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma cells from substratum in vitro. Arch Dermatol Res 2011; 303:499-512; PMID:21274549; http://dx.doi.org/10.1007/s00403-011-1121-4.
9. Griffin L, Lawson A. Antibody fragments as tools in crystallography. Clin Exp Immunol 2011; 165:285-91; PMID:21649648; http://dx.doi.org/10.1111/j.1365- 2249.2011.04427.x.
10. Iwata S, Ostermeier C, Ludwig B, Michel H. Structure at 2.8 A resolution of cytochrome c oxidase from Paracoccus denitrificans. Nature 1995; 376:660-9; PMID:7651515; http://dx.doi.org/10.1038/376660a0.
11. Skerra A. Engineered protein scaffolds for molecular recognition. J Mol Recognit 2000; 13:167-87; PMID:10931555; http://dx.doi. org/10.1002/1099- 1352(200007/08)13:4<167::AID-JMR502>3.0.CO;2-9.
12. Binz HK, Plückthun A. Engineered proteins as specific binding reagents. Curr Opin Biotechnol 2005; 16:459-69; PMID:16005204; http://dx.doi.org/10.1016/j.copbio.2005.06.005.
13. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245-55; PMID:19501012; http://dx.doi.org/10.1016/j.cbpa.2009.04.627.
14. Musacchio A, Wilmanns M, Saraste M. Structure and function of the SH3 domain. Prog Biophys Mol Biol 1994; 61:283-97; PMID:8073124; http://dx.doi.org/10.1016/0079-6107(94)90003-5.
15. Grabulovski D, Kaspar M, Neri DA. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 2007; 282:3196-204; PMID:17130124; http://dx.doi.org/10.1074/jbc. M609211200.
16. Bertschinger J, Grabulovski D, Neri D. Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel 2007; 20:57-68; PMID:17242027; http://dx.doi.org/10.1093/protein/gzl055.
17. Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 2000; 326:480-505; PMID:11036659; http://dx.doi.org/10.1016/S0076-6879(00)26071- 0.
18. Semba K, Nishizawa M, Miyajima N, Yoshida MC, Sukegawa J, Yamanashi Y, et al. yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family. Proc Natl Acad Sci USA 1986; 83:5459-63; PMID:3526330; http://dx.doi.org/10.1073/pnas.83.15.5459.
19. Kawakami T, Pennington CY, Robbins KC. Isolation and oncogenic potential of a novel human src-like gene. Mol Cell Biol 1986; 6:4195-201; PMID:3099169.
20. Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A, et al. Design, construction and characterization of a large synthetic human antibody phage display library. Proteomics 2005; 5:2340-50; PMID:15880779; http://dx.doi.org/10.1002/pmic.200401273.
21. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci USA 2006; 103:4586- 91; PMID:16537393; http://dx.doi.org/10.1073/ pnas.0505379103.
22. Sennhauser G, Grütter MG. Chaperone-assisted crystallography with DARPins. Structure 2008; 16:1443-53; PMID:18940601; http://dx.doi.org/10.1016/j. str.2008.08.010.
23. Monroe N, Sennhauser G, Seeger MA, Briand C, Grütter MG. Designed ankyrin repeat protein binders for the crystallization of AcrB: plasticity of the dominant interface. J Struct Biol 2011; 174:269-81; PMID:21296164; http://dx.doi.org/10.1016/j.jsb.2011.01.014.
24. c-nanobody complexes. Protein Eng Des Sel 2011; 24:737-41; PMID:21536542; http://dx.doi.org/10.1093/protein/gzr017.
25. Steyaert J, Kobilka BK. Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol 2011; 21:567-72; PMID:21782416; http://dx.doi.org/10.1016/j.sbi.2011.06.011.
26. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991; 19:4133-7; PMID:1908075; http://dx.doi.org/10.1093/nar/19.15.4133.
27. Perspicace S, Banner D, Benz J, Müller F, Schlatter D, Huber W. Fragment-based screening using surface plasmon resonance technology. J Biomol Screen 2009; 14:337-49; PMID:19403917; http://dx.doi.org/10.1177/ 1087057109332595.
28. Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr 2010; 66:125-32; PMID:20124692; http://dx.doi.org/10.1107/S0907444909047337.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658-74; PMID:19461840; http://dx.doi.org/10.1107/S0021889807021206.
30. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53:240-55; PMID:15299926; http://dx.doi.org/10.1107/S0907444996012255.
31. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994; 50:760-3; PMID:15299374; http://dx.doi.org/10.1107/S0907444994003112.
32. Bricogne G. Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives. Acta Crystallogr D Biol Crystallogr 1993; 49:37-60; PMID:15299544; http://dx.doi.org/10.1107/ S0907444992010400.
33. Roversi P, Blanc E, Vonrhein C, Evans G, Bricogne G. Modelling prior distributions of atoms for macromolecular refinement and completion. Acta Crystallogr D Biol Crystallogr 2000; 56:1316-23; PMID:10998628; http://dx.doi.org/10.1107/S0907444900008490.
34. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, Bricogne G. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr 2004; 60:2210-21; PMID:15572774; http://dx.doi.org/10.1107/S0907444904016427.
35. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010; 66:213-21; PMID:20124702; http://dx.doi.org/10.1107/S0907444909052925.
36. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-32; PMID:15572765; http://dx.doi.org/10.1107/S0907444904019158.